1421 - Safety and Efficacy of Zanubrutinib in a Subgroup of Older Patients (≥75 Years) With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma From the SEQUOIA Study

Primary Author / Presenter(s)

A�

Anders Österborg, MD, PhD

Department of Oncology-Pathology, Karolinska Institutet; Department of Hematology, Karolinska University Hospital
Stockholm, Stockholms Lan, Sweden
Talha Munir, MBBS, MRCP, FRCPath, PhD

Consultant Haematologist
Leeds Teaching Hospitals NHS Trust
Leeds, England, United Kingdom
PW

Patricia Walker, MD

Peninsula Health and Peninsula Private Hospital
Melbourne, Australia
Tadeusz Robak, MD, PhD

Professor of Hematology; Head, Department of General Hematology & Internal Medicine
Department of Hematology, Medical University of Lodz; Department of General Hematology and Internal Medicine, Copernicus Memorial Hospital
Łódź, Lodzkie, Poland
HC

Hanna Ciepluch, PhD

Copernicus Regional Oncology Centre
Gdansk, Poland
RG

Richard Greil, MD

Professor
Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria; Cancer Cluster Salzburg
Salzburg, Austria
TT

Tian Tian

BeOne Medicines Ltd
San Carlos, California, United States
ML

Marcus Lefebure, PhD

BeOne Medicines Ltd
London, England, United Kingdom
JH

Jamie Hirata, PharmD

BeOne Medicines Ltd
San Carlos, California, United States
CT

Constantine S. Tam, MD, MBBS

Consultant Haematologist
Alfred Hospital and Monash University
Melbourne, Victoria, Australia